Hyperinsulinemia, a hallmark of T2DM, directly exerts mitogenic effects and enhances IGF-1 bioactivity, activating PI3K/Akt and MAPK pathways to inhibit apoptosis and stimulate cell proliferation, thereby increasing cancer risk [17–19]. Here, AKT1 is linked to Hyperinsulinemia.